Long-term pancreatic cancer survivors have been found to have significant immunogenic neoantigens and robust CD8+ T cell infiltrations, demonstrating that neoantigen-based cancer immunotherapies could prolong survival [58]. The gene discussed is CD8A; the disease is cancer.